216 related articles for article (PubMed ID: 35950920)
61. Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia.
Petrović N; Mandušić V; Dimitrijević B; Roganović J; Lukić S; Todorović L; Stanojević B
Med Oncol; 2014 Jun; 31(6):977. PubMed ID: 24781337
[TBL] [Abstract][Full Text] [Related]
62. Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures.
Tasdemir N; Bossart EA; Li Z; Zhu L; Sikora MJ; Levine KM; Jacobsen BM; Tseng GC; Davidson NE; Oesterreich S
Cancer Res; 2018 Nov; 78(21):6209-6222. PubMed ID: 30228172
[TBL] [Abstract][Full Text] [Related]
63. Invasive lobular carcinoma: clinicopathological features and subtypes.
Danzinger S; Hielscher N; Izsó M; Metzler J; Trinkl C; Pfeifer C; Tendl-Schulz K; Singer CF
J Int Med Res; 2021 Jun; 49(6):3000605211017039. PubMed ID: 34187216
[TBL] [Abstract][Full Text] [Related]
64. Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment.
Onkar S; Cui J; Zou J; Cardello C; Cillo AR; Uddin MR; Sagan A; Joy M; Osmanbeyoglu HU; Pogue-Geile KL; McAuliffe PF; Lucas PC; Tseng GC; Lee AV; Bruno TC; Oesterreich S; Vignali DAA
Nat Cancer; 2023 Apr; 4(4):516-534. PubMed ID: 36927792
[TBL] [Abstract][Full Text] [Related]
65. Expression of Lipid Metabolism-Related Proteins Differs between Invasive Lobular Carcinoma and Invasive Ductal Carcinoma.
Cha YJ; Kim HM; Koo JS
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28124996
[TBL] [Abstract][Full Text] [Related]
66. Lack of CD151/integrin α3β1 complex is predictive of poor outcome in node-negative lobular breast carcinoma: opposing roles of CD151 in invasive lobular and ductal breast cancers.
Romanska HM; Potemski P; Krakowska M; Mieszkowska M; Chaudhri S; Kordek R; Kubiak R; Speirs V; Hanby AM; Sadej R; Berditchevski F
Br J Cancer; 2015 Nov; 113(9):1350-7. PubMed ID: 26418423
[TBL] [Abstract][Full Text] [Related]
67. Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer.
Oesterreich S; Nasrazadani A; Zou J; Carleton N; Onger T; Wright MD; Li Y; Demanelis K; Ramaswamy B; Tseng G; Lee AV; Williams N; Kruse M
J Natl Cancer Inst; 2022 Nov; 114(11):1511-1522. PubMed ID: 36239760
[TBL] [Abstract][Full Text] [Related]
68. A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population.
Lim ST; Yu JH; Park HK; Moon BI; Ko BK; Suh YJ
World J Surg Oncol; 2014 Mar; 12():56. PubMed ID: 24621330
[TBL] [Abstract][Full Text] [Related]
69. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
70. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.
Cocquyt VF; Blondeel PN; Depypere HT; Praet MM; Schelfhout VR; Silva OE; Hurley J; Serreyn RF; Daems KK; Van Belle SJ
Eur J Surg Oncol; 2003 May; 29(4):361-7. PubMed ID: 12711290
[TBL] [Abstract][Full Text] [Related]
71. The Real-world Outcomes of Patients With Advanced Invasive Lobular Carcinoma of the Breast Compared With Invasive Ductal Carcinoma: A Review at a Single Institution.
Watanabe J; Nakamoto S; Sugino T
Anticancer Res; 2021 Sep; 41(9):4619-4627. PubMed ID: 34475090
[TBL] [Abstract][Full Text] [Related]
72. Does routine grading of invasive lobular cancer of the breast have the same prognostic significance as for ductal cancers?
Sinha PS; Bendall S; Bates T
Eur J Surg Oncol; 2000 Dec; 26(8):733-7. PubMed ID: 11087636
[TBL] [Abstract][Full Text] [Related]
73. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
Lips EH; Mukhtar RA; Yau C; de Ronde JJ; Livasy C; Carey LA; Loo CE; Vrancken-Peeters MJ; Sonke GS; Berry DA; Van't Veer LJ; Esserman LJ; Wesseling J; Rodenhuis S; Shelley Hwang E;
Breast Cancer Res Treat; 2012 Nov; 136(1):35-43. PubMed ID: 22961065
[TBL] [Abstract][Full Text] [Related]
74. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
Yamaguchi N; Nakayama Y; Yamaguchi N
J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
[TBL] [Abstract][Full Text] [Related]
75. Clinical outcomes using accelerated partial breast irradiation in patients with invasive lobular carcinoma.
Shah C; Wilkinson JB; Shaitelman S; Grills I; Wallace M; Mitchell C; Vicini F
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e547-51. PubMed ID: 21640491
[TBL] [Abstract][Full Text] [Related]
76. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology.
Moran MS; Yang Q; Haffty BG
Breast J; 2009; 15(6):571-8. PubMed ID: 19995377
[TBL] [Abstract][Full Text] [Related]
77. Metastatic profiles and survival differences between infiltrating ductal carcinoma and infiltrating lobular carcinoma in invasive breast cancer.
Cavaller L; Goupille C; Arbion F; Vilde A; Body G; Ouldamer L
J Gynecol Obstet Hum Reprod; 2024 Apr; 53(4):102740. PubMed ID: 38311000
[TBL] [Abstract][Full Text] [Related]
78. Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience.
Okines A; Irfan T; Asare B; Mohammed K; Osin P; Nerurkar A; Smith IE; Parton M; Ring A; Johnston S; Turner NC
Breast Cancer Res Treat; 2022 Apr; 192(3):563-571. PubMed ID: 35119530
[TBL] [Abstract][Full Text] [Related]
79. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
80. Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma.
Cao L; Basudan A; Sikora MJ; Bahreini A; Tasdemir N; Levine KM; Jankowitz RC; McAuliffe PF; Dabbs D; Haupt S; Haupt Y; Lucas PC; Lee AV; Oesterreich S; Atkinson JM
Cancer Lett; 2019 Oct; 461():21-30. PubMed ID: 31229512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
